
| Iupac Name: | (4Z)-2-Fluoro-4-(5-hydroxy-7-vinyl-1,3-benzoxazol-2(3H)-ylidene)-2,5-cyclohexadien-1-one |
| Image Class: | skin-invert-image |
| Width: | 250 |
| Cas Number: | 524684-52-4 |
| Unii: | A9C8MNF7CA |
| Atc Prefix: | None |
| Pubchem: | 5326893 |
| Chemspiderid: | 4484184 |
| C: | 15 |
| H: | 10 |
| F: | 1 |
| N: | 1 |
| O: | 3 |
| Smiles: | O=C3\C=C/C(=C2/Oc1c(cc(O)cc1N2)\C=C)/C=C3/F |
| Stdinchi: | 1S/C15H10FNO3/c1-2-8-5-10(18)7-12-14(8)20-15(17-12)9-3-4-13(19)11(16)6-9/h2-7,17-18H,1H2/b15-9- |
| Stdinchikey: | FCXYSEXZEGPLGG-DHDCSXOGSA-N |
Prinaberel (INN, USAN) (developmental code names ERB-041, WAY-202041) is a synthetic, nonsteroidal, and highly selective agonist of the ERβ subtype of the estrogen receptor.[1] It is used in scientific research to elucidate the role of the ERβ receptor.[2] Studies have indicated that selective ERβ agonists like prinaberel could be useful in the clinical treatment of a variety of medical conditions including inflammatory bowel disease, rheumatoid arthritis, endometriosis, and sepsis.[3] Accordingly, prinaberel either was or still is under investigation by Wyeth for the treatment of some of these conditions.[4]